The implementation will occur as part of a multi-year agreement that aims to improve patient care by giving clinicians clinical decision-making support and access to data from relevant clinical trials.
Philips IntelliSpace Precision Medicine is a system that brings together genomic data, disease histology and patient phenotype to give clinicians a comprehensive picture of a patient.
The agreement between Miami Cancer Institute and Philips will also advance the former’s launch of the TruSight Tumor 170 next-generation sequencing testing service, in collaboration with Illumina and N-of-One. The Philips system will help with data capture and storage.
More articles on healthcare quality:
Why some hospitals are offering essential oils to surgery patients
Former CDC leader on bird flu threat: ‘We don’t know how the story’s going to end’
Hospitals send many patients home with ‘risky’ antibiotics, study finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
